External auditory canal aplasia/hypoplasia

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:141074OMIM:108760Q16.1
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

What is External auditory canal aplasia/hypoplasia?

External auditory canal aplasia/hypoplasia refers to the congenital absence (aplasia) or underdevelopment (hypoplasia) of the external ear canal, the passage that leads from the outer ear (pinna) to the eardrum (tympanic membrane). This condition is also known as aural atresia or external auditory canal atresia/stenosis. It results from abnormal development of the first branchial groove during embryonic life and primarily affects the auditory system. The condition may occur unilaterally (one ear) or bilaterally (both ears) and leads to conductive hearing loss because sound cannot travel normally through the ear canal to reach the middle ear structures. It is frequently associated with other external and middle ear malformations, including microtia (underdevelopment of the outer ear), ossicular chain abnormalities, and occasionally inner ear anomalies. External auditory canal aplasia/hypoplasia can occur as an isolated finding or as part of broader syndromic conditions such as Treacher Collins syndrome, Goldenhar syndrome (oculo-auriculo-vertebral spectrum), or branchio-oto-renal syndrome. The key clinical feature is hearing loss, which can significantly impact speech and language development, particularly when bilateral. Diagnosis is typically made at birth or in early infancy through clinical examination and confirmed with imaging studies such as high-resolution computed tomography (CT) of the temporal bones, which helps delineate the anatomy of the ear canal, middle ear, and inner ear. Audiological evaluation, including auditory brainstem response (ABR) testing, is essential to assess the degree and type of hearing loss. Management depends on the severity and whether the condition is unilateral or bilateral. Early hearing rehabilitation is critical, especially in bilateral cases, and may include bone-conduction hearing aids (such as bone-anchored hearing aids or softband devices) to ensure adequate auditory input during critical periods of speech and language development. Surgical reconstruction of the ear canal (canaloplasty or atresiaplasty) may be considered in selected patients, typically after age 5-6 years, based on favorable middle ear anatomy as assessed by CT imaging. Patients require long-term follow-up by a multidisciplinary team including otolaryngologists, audiologists, and speech-language pathologists.

Also known as:

Inheritance
Variable
Can be inherited in different ways depending on the underlying gene
Age of Onset
Neonatal
Begins at or shortly after birth (first 4 weeks)
Orphanet ↗OMIM ↗NORD ↗

Treatments

Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly

No FDA-approved treatments are currently listed for External auditory canal aplasia/hypoplasia.

View clinical trials →

Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest

No actively recruiting trials found for External auditory canal aplasia/hypoplasia at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the External auditory canal aplasia/hypoplasia community →

Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)

No specialists are currently listed for External auditory canal aplasia/hypoplasia.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers

Source: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months

🏨 Children's

Children's Hospital Colorado Rare Disease Program

Children's Hospital Colorado

📍 Aurora, CO

👤 Boston Children's Hospital Rare Disease Program

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Boston Children's Hospital Rare Disease Program

Boston Children's Hospital

📍 Boston, MA

👤 Boston Children's Hospital Rare Disease Program

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

🏨 Children's

Ann & Robert H. Lurie Children's Hospital Genetics

Lurie Children's Hospital

📍 Chicago, IL

👤 Boston Children's Hospital Rare Disease Program

🏥 NORD

Cincinnati Children's Hospital Medical Center

Cincinnati Children's

📍 Cincinnati, OH

👤 Boston Children's Hospital Rare Disease Program

🏨 Children's

Nationwide Children's Hospital Rare Disease Center

Nationwide Children's Hospital

📍 Columbus, OH

👤 Boston Children's Hospital Rare Disease Program

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

Travel Grants

No travel grants are currently matched to External auditory canal aplasia/hypoplasia.

Search all travel grants →NORD Financial Assistance ↗

Community

Open External auditory canal aplasia/hypoplasiaForum →

No community posts yet. Be the first to share your experience with External auditory canal aplasia/hypoplasia.

Start the conversation →

Latest news about External auditory canal aplasia/hypoplasia

Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC

No recent news articles for External auditory canal aplasia/hypoplasia.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about External auditory canal aplasia/hypoplasia

What is External auditory canal aplasia/hypoplasia?

External auditory canal aplasia/hypoplasia refers to the congenital absence (aplasia) or underdevelopment (hypoplasia) of the external ear canal, the passage that leads from the outer ear (pinna) to the eardrum (tympanic membrane). This condition is also known as aural atresia or external auditory canal atresia/stenosis. It results from abnormal development of the first branchial groove during embryonic life and primarily affects the auditory system. The condition may occur unilaterally (one ear) or bilaterally (both ears) and leads to conductive hearing loss because sound cannot travel normal

At what age does External auditory canal aplasia/hypoplasia typically begin?

Typical onset of External auditory canal aplasia/hypoplasia is neonatal. Age of onset can vary across affected individuals.

Frequently asked questions about External auditory canal aplasia/hypoplasia

Auto-generated from canonical disease facts (Orphanet, OMIM, ClinicalTrials.gov, openFDA, NPPES). Not a substitute for clinical guidance.

  1. What is External auditory canal aplasia/hypoplasia?

    External auditory canal aplasia/hypoplasia is a rare disease catalogued in international rare-disease ontologies (Orphanet ORPHA:141074, OMIM 108760). It is typically inherited as variable. Age of onset is generally neonatal. For verified primary sources, see the UniteRare External auditory canal aplasia/hypoplasia page.

  2. How is External auditory canal aplasia/hypoplasia inherited?

    External auditory canal aplasia/hypoplasia follows variable inheritance. Genetic counseling is recommended for affected families to understand recurrence risk in offspring and the likelihood of unaffected siblings being carriers. Variants in the underlying gene(s) may be identified via clinical genetic testing.

  3. Are there FDA-approved treatments for External auditory canal aplasia/hypoplasia?

    Approved treatments for External auditory canal aplasia/hypoplasia are tracked from openFDA and DailyMed primary sources. Many rare diseases have no specific FDA-approved therapy; for those, supportive care and management of complications form the basis of clinical care. Orphan-drug-designation status is noted where applicable.

  4. Are there clinical trials for External auditory canal aplasia/hypoplasia?

    Active clinical trials for External auditory canal aplasia/hypoplasia are tracked daily from ClinicalTrials.gov. Trial availability changes frequently; check the UniteRare trial listings for the current count and recruitment status. Sponsors of rare-disease research often welcome inquiries even when a trial is not actively recruiting at a given moment.

  5. How do I find a specialist for External auditory canal aplasia/hypoplasia?

    Verified External auditory canal aplasia/hypoplasia specialists are identified through ClinicalTrials.gov principal-investigator records, peer-reviewed publication authorship (via PubMed), and the NPPES NPI registry. NORD-designated Centers of Excellence and NIH-affiliated rare-disease clinics are also tracked. UniteRare's specialist directory is updated continuously as new evidence becomes available.

See full External auditory canal aplasia/hypoplasia page for complete clinical details, sources, and verified-specialist listings.

Cite this page

Select a citation format above to view and copy.